Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 25;27(1):10.
doi: 10.1007/s11883-024-01248-w.

Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review

Elena Olmastroni  1   2 , Stefano Scotti  1   2 , Federica Galimberti  2 , Sining Xie  1 , Manuela Casula  3   4
Affiliations
Review

Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review

Elena Olmastroni et al. Curr Atheroscler Rep. .

Abstract

Purpose of review: To consolidate key information on the efficacy and safety of ezetimibe, with a focus on the latest evidence.

Recent findings: While ezetimibe has long been used alongside statins to help achieve lipid goals when statins are insufficient or in statin-intolerant patients, recent studies confirm and extend its benefits. Ezetimibe, when added to statins, is now recognized as an effective option for high-risk cardiovascular patients. Additionally, for those intolerant to statins, it can be combined with bempedoic acid, offering significant LDL cholesterol reduction. Ezetimibe's favourable tolerability, with fewer side effects than statins, along with the availability of fixed-dose combinations, enhances both treatment efficacy and patient adherence. Overall, this review underscores ezetimibe's evolving role in lipid management, providing valuable guidance for optimizing cardiovascular risk reduction strategies.

Keywords: Combination therapy; Ezetimibe; Statin intolerance; Treatment adherence.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human and Animal Rights and Informed Consent: This article is a review and does not contain any studies with human participants or animals performed by any of the authors. As no original data was collected, ethical approval and informed consent were not required. Conflict of Interest: All authors declare no support from any organization for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. Competing Interests: The authors declare no competing interests.

References

    1. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The heart of the World. Glob Heart. 2024;19(1):11. - PubMed - PMC - DOI
    1. Mortensen MB, Dzaye O, Botker HE, Jensen JM, Maeng M, Bentzon JF, et al. Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis: the western Denmark heart registry. Circulation. 2023;147(14):1053–63. - PubMed - PMC - DOI
    1. Ruscica M, Bertoletti A, Gobbi C, Sirtori CR, Carugo S, Corsini A. Lipid-lowering approaches to manage statin-intolerant patients. Eur Heart J Suppl. 2024;26(Suppl 1):i56–9. - PubMed - PMC - DOI
    1. Bays HE. Cholesterol-lowering drugs: Focus on Ezetimibe: cholesterol-lowering drugs: focus on ezetimibe. Eur Atherosclerosis J. 2022;1(1):14–24. - DOI
    1. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–94. - PubMed - DOI

MeSH terms

LinkOut - more resources